Deals
AstraZeneca Pays CSPC $30M for $1.77B Kidney Deal
AstraZeneca puts just $30M down now to control up to $1.77B in kidney-drug milestones, its fourth check written to Chinese partner CSPC since 2024.
Deals — Page 3
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Payward Buys Reap for $600M in Stablecoin Bet
Kraken's parent paid up to $600M for a Hong Kong payments firm — here's what Payward actually bought, and why the discount to Stripe's Bridge deal.
Deals
Ipsen Pays $796M for Memo, No Per-Share Premium in Sight
No share price, no premium to measure. Just a binary bet: $227M upfront now, up to $796M if potravitug clears its kidney-transplant trial.
Deals
Fed's $16.6B Pandemic Loan Book Bleeds $2B More
A federal lending program built to rescue small businesses now owes taxpayers an answer: why is a third of its $16.6B book underwater?
Deals
Bidders Balk at Atom Bank's £600M Ask
Atom Bank's £600M auction couldn't find a full-price buyer, and shareholders are now weighing whether management should pay the price.
Deals
Elroy Air Nears $1B SPAC Via Columbus Circle
Elroy Air's cargo drone, built to replace trucks on middle-mile routes, could hit public markets by Friday via a $1B SPAC with Columbus Circle.
Deals
World Leaks Dumped Apple iPhone Schematics from Tata
World Leaks posted 200,000 files from Tata's breach, including Apple iPhone schematics and PCB designs. Dell and Nike were the warm-up.
Deals
Walmart Bought Vibe.co to Crack Streaming TV for SMBs
Walmart's undisclosed Vibe.co deal plugs the SMB gap in its CTV stack, coming one day after it unified ad ops across Walmart Connect and Sam's Club.
Deals
Sangamo Filed Chapter 11; Lilly Bids $50M for Platforms
Lilly converts a $1.4B milestone obligation into a $50M clean platform buy; Sangamo's Chapter 11 shows how bankruptcy reshapes deal math.
Deals
Nuvectis Buys Haisco Factor B Rights for $40M
Nuvectis paid $40M upfront for ex-China rights to Haisco's once-daily Factor B inhibitor in a PNH market projected above $5B in 2026.
Deals
Insilico Bags $2.5B SK Deal, $18M Upfront and Near-Term
SK Biopharmaceuticals is putting $18M upfront on a $2.5B Insilico neuroimmune deal — and the backloaded structure tells you who blinked.
Deals
Hits $2B Revenue, Kalshi Eyes IPO
Kalshi hit $2B in annualized revenue, doubled its valuation in five months, and is now talking to banks about an IPO it won't need until 2027.
Deals
Memento Raises $93M, Buys VEGF-Tie2 Eye Bispecific
Memento raised $93M and licensed a VEGF-Tie2 bispecific for nAMD and DME, conditions driving $4.4B in U.S. Eylea franchise sales last year.
Deals
Disabled: Salesforce Cuts Klue App After OAuth Token Theft
A dormant API credential let Icarus harvest OAuth tokens from Klue, taking CRM data from Huntress and prompting Salesforce to pull the plug.
Deals
Icarus Hacked 7 Firms via Klue OAuth Breach
Icarus extortion group turned a dormant Klue API credential into a Salesforce pivot hitting Recorded Future, Huntress, and five more firms.
Deals
Accenture Buys Dragos Trio in $4.2B OT Security Deal
Accenture paid roughly 20x ARR for Dragos, runZero, and NetRise, betting AI threats will turn a $27B OT security market into $59B by 2031.
Deals
Cleared: Santander's $12.3B Webster Deal Needs Fed
Santander's $12.3B Webster bid cleared OCC in 74 days, but Fed, ECB, and DOJ reviews still stand between Santander and a $327B U.S. lender.
Deals
OCC Cleared Santander's $12.2B Webster Buy
Santander's $12.2B Webster deal cleared the OCC, but the Federal Reserve and ECB still hold the pen on a close worth $75 per share.
Deals
Jazz Paid $56M Upfront in $2.46B AbCellera Deal
Jazz dropped $56M to option into AbCellera's T cell engager pipeline for GI cancer, days after Zepzelca's Phase 3 failed its SCLC expansion.
Deals
SpaceX Bought Cursor for $60B Days After IPO
SpaceX's $60B Cursor deal prices the startup at 23x revenue. Days after the IPO. The catch: Anthropic already controls half the AI coding market.
